Introduction

Managing PLA2R-associated membranous nephropathy often involves complex therapeutic choices. While many practitioners utilize rituximab as a first-line agent, the timeline for assessing clinical success remains a subject of debate. Furthermore, some patients exhibit a slow improvement rate that may lead to premature treatment escalation. Therefore, clinicians must understand the latency between immunological and clinical responses to optimize patient outcomes.

Monitoring PLA2R-associated membranous nephropathy

A 46-year-old male presenting with severe proteinuria initially failed high-dose glucocorticoid therapy. Consequently, the medical team initiated a low-dose, fractionated rituximab regimen totaling 3.6 g over 14 months. Notably, the patient did not show a significant reduction in proteinuria until 19 months after the first dose. However, he eventually reached partial remission at that stage and progressed to complete remission by month 27. Similarly, his anti-PLA2R antibodies remained negative throughout the follow-up period.

Moreover, this durable remission persisted even as circulating CD19+ B cells began to reconstitute. This observation suggests that B-cell repopulation does not necessarily signal an impending relapse if antibody levels remain suppressed. Thus, specialists should prioritize longitudinal monitoring of anti-PLA2R antibody titers over B-cell counts. Additionally, this approach helps avoid unnecessary retreatment in slow responders who are already on the path to recovery.

FAQ

Why is clinical remission often delayed in PLA2R-associated membranous nephropathy?

Remission lags behind immunological response because the kidney requires time to clear existing subepithelial immune deposits. Even after antibodies disappear, proteinuria may take months to decline significantly while the glomerular basement membrane heals.

Does B-cell reconstitution require immediate retreatment?

Not necessarily. If anti-PLA2R antibodies remain undetectable, B-cell reconstitution does not typically indicate a disease relapse. Consequently, clinicians should monitor antibody trends rather than relying solely on B-cell counts to guide therapy.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Yang R et al. Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report. BMC Nephrol. 2026 Apr 13. doi: 10.1186/s12882-026-04830-3. PMID: 41975315.

2. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276.

3. Beck LH Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol. 2011;22(8):1543-1550.